Beximco Pharmaceuticals logo

BXP - Beximco Pharmaceuticals Share Price

85.5p 0.0  0.0%

Last Trade - 10/05/21

Mid Cap
Market Cap £381.4m
Enterprise Value £451.9m
Revenue £240.1m
Position in Universe 671st / 1821
Unlock BXP Revenue
Relative Strength (%)
1m -4.01%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -22.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
11,207 20,035 15,509 17,717 22,817 25,612 22,361 24,811 +18.0%
+8.8 +102.8 -28.0 +13.8 +19.6 +16.8 -3.03 +13.3
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 31 March 2021, BeximcoPharmaceuticals Limited revenues increased 14% toBDT21.76B. Net income increased 40% to BDT3.67B. Revenuesreflect an increase in demand for the Company's productsand services due to favorable market conditions. Net incomebenefited from Labor & Related Expenses in SG decrease of66% to BDT521M (expense), Selling, Marketing andDistribution Expe decrease of 61% to BDT368.6M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BXP Revenue Unlock BXP Revenue

Net Income

BXP Net Income Unlock BXP Revenue

Normalised EPS

BXP Normalised EPS Unlock BXP Revenue

PE Ratio Range

BXP PE Ratio Range Unlock BXP Revenue

Dividend Yield Range

BXP Dividend Yield Range Unlock BXP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BXP EPS Forecasts Unlock BXP Revenue
Profile Summary

Beximco Pharmaceuticals Limited (BPL) is engaged in the manufacturing and marketing of generic pharmaceuticals formulation products, including intravenous fluids and active pharmaceutical ingredients (APIs). The Company also provides contract manufacturing services. The Company produces approximately 300 generic medicines, which are available in over 500 different presentations and the portfolio encompasses various key therapeutic categories, including antibiotics, analgesics, anti-diabetic, respiratory, cardiovascular, central nervous system, dermatology and gastrointestinal. Its product categories also include anti-infectives, musculoskeletal, oncology, respiratory, skin care, vitamins and minerals supplement, and others. The Company's products include Acifix, Femzole, Q-Rash, Tamona, Taverin, Tobasol, IcyKool Cream, Intracef, Gastalfet, Iprasol, Calorate, Gentosep and others. BPL's products are sold in domestic and international markets.

Last Annual June 30th, 2020
Last Interim March 31st, 2021
Incorporated December 31, 1976
Public Since October 21, 2005
No. of Shareholders: 56,101
No. of Employees: 2,310
Sector Healthcare
Industry Pharmaceuticals
Exchange London Stock Exchange (Dual Listing)
Shares in Issue 446,112,536
Free Float (0.0%)
Eligible for
× ISAs
BXP Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BXP
Upcoming Events for BXP
Frequently Asked Questions for Beximco Pharmaceuticals
What is the Beximco Pharmaceuticals share price?

As of 10/05/21, shares in Beximco Pharmaceuticals are trading at 85.5p, giving the company a market capitalisation of £381.4m. This share price information is delayed by 15 minutes.

How has the Beximco Pharmaceuticals share price performed this year?

Shares in Beximco Pharmaceuticals are currently trading at 85.5p and the price has moved by 0.129k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Beximco Pharmaceuticals price has moved by 86.22% over the past year.

What are the analyst and broker recommendations for Beximco Pharmaceuticals?

Of the analysts with advisory recommendations for Beximco Pharmaceuticals, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Beximco Pharmaceuticals is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Beximco Pharmaceuticals next release its financial results?

Beximco Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Beximco Pharmaceuticals dividend yield?

The Beximco Pharmaceuticals dividend yield is 1.35% based on the trailing twelve month period.

Does Beximco Pharmaceuticals pay a dividend?

Last year, Beximco Pharmaceuticals paid a total dividend of 1.36, and it currently has a trailing dividend yield of 1.35%. Looking ahead, Beximco Pharmaceuticals has not announced an ex-dividend date yet.

When does Beximco Pharmaceuticals next pay dividends?

Beximco Pharmaceuticals has yet to annouce their ex-dividend date. The historic dividend yield on Beximco Pharmaceuticals shares is currently 1.35%.

How do I buy Beximco Pharmaceuticals shares?

To buy shares in Beximco Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Beximco Pharmaceuticals?

Shares in Beximco Pharmaceuticals are currently trading at 85.5p, giving the company a market capitalisation of £381.4m.

Where are Beximco Pharmaceuticals shares listed? Where are Beximco Pharmaceuticals shares listed?

Here are the trading details for Beximco Pharmaceuticals:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: BXP
What kind of share is Beximco Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, Beximco Pharmaceuticals is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Beximco Pharmaceuticals share price forecast 2021?

Shares in Beximco Pharmaceuticals are currently priced at 85.5p. At that level they are trading at 99.17% premium to the analyst consensus target price of 42.93.

Analysts covering Beximco Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of 7.695499871 for the next financial year.

How can I tell whether the Beximco Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beximco Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been 15.31%. At the current price of 85.5p, shares in Beximco Pharmaceuticals are trading at 14.65% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Beximco Pharmaceuticals PE Ratio?

The Beximco Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 9.85. The shares are currently trading at 85.5p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Beximco Pharmaceuticals?

Beximco Pharmaceuticals's management team is headed by:

Ahmed Rahman - CHM
Ahmed Rahman - VCH
Iqbal Ahmed - DRC
Mohammad Qasem - DRC
Osman Chowdhury - OTH
Abu Bakar Siddiqur Rahman - DRC
Nazmul Hassan - CEO
Ali Nawaz - CFO
Afsar Ahmed - OTH
Rabbur Reza - COO
Zakaria Chowdhury - DSL
Abdur Rahman - OTH
Jamal Choudhury - GMG
Quamrun Ahmed - NED
Reem Shamsuddoha - NED
Who are the major shareholders of Beximco Pharmaceuticals?

Here are the top five shareholders of Beximco Pharmaceuticals based on the size of their shareholding:

Stonehage Fleming Investment Management Limited Investment Advisor
Percentage owned: 1.03% (4.60m shares)
Evli Fund Management Company Ltd. Investment Advisor
Percentage owned: 0.97% (4.34m shares)
Evli Emerging Frontier B Mutual Fund
Percentage owned: 0.97% (4.34m shares)
Percentage owned: 0.84% (3.75m shares)
Alpha Investments Asia Mutual Fund
Percentage owned: 0.34% (1.52m shares)
Similar to BXP
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.